本帖最后由 老马 于 2012-1-13 21:20 编辑 , Q5 z ?$ Y! }6 H: l+ }7 s @
! W! g9 ^0 ]! V- n爱必妥和阿瓦斯丁的比较* H% w% _. T; d7 Y& N/ d& b
) u2 i% ]. u, c" @% {$ W, u+ L
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ b6 ]& P, ?6 U5 y0 e
7 n/ v4 a7 ?+ Q. {
4 v- j8 a! {8 q* T( B" w% Thttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
! K5 m4 Q0 M9 c c; g/ |==================================================) [* Q" \& L; E
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 }& X. V# Z$ n5 h5 o @Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." d" o# l2 x4 `, B, \# u2 [
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.# _2 ?' X0 u1 \5 ]7 K, a
|